Kara M. Kelly

Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

PET Response and Outcome in Low‐Risk Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

Personalized Impression Generation for PET Reports Using Large Language Models

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Pediatric Hodgkin Lymphoma, Version 3.2021

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis

Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement

Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes

Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer

Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents

Pediatric Lymphomas and Histiocytic Disorders of Childhood

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia

Genetic loss of SH2B3 in acute lymphoblastic leukemia

Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Topical Yunnan Baiyao administration as an adjunctive therapy for bleeding complications in adolescents with advanced cancer